Larson Financial Group LLC Has $937,000 Holdings in Pfizer Inc. (NYSE:PFE)

Larson Financial Group LLC lifted its position in shares of Pfizer Inc. (NYSE:PFE) by 49.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 33,769 shares of the biopharmaceutical company’s stock after purchasing an additional 11,101 shares during the quarter. Larson Financial Group LLC’s holdings in Pfizer were worth $937,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Clifford Swan Investment Counsel LLC grew its holdings in shares of Pfizer by 4.7% during the 4th quarter. Clifford Swan Investment Counsel LLC now owns 417,070 shares of the biopharmaceutical company’s stock worth $12,007,000 after purchasing an additional 18,611 shares in the last quarter. LifePlan Financial LLC acquired a new stake in Pfizer in the 4th quarter valued at $255,000. Cantor Fitzgerald Investment Advisors L.P. acquired a new stake in Pfizer in the 4th quarter valued at $16,166,000. KLCM Advisors Inc. boosted its stake in Pfizer by 75.0% in the 4th quarter. KLCM Advisors Inc. now owns 173,793 shares of the biopharmaceutical company’s stock valued at $5,004,000 after buying an additional 74,487 shares in the last quarter. Finally, Farmers Trust Co. boosted its stake in Pfizer by 2.0% in the 4th quarter. Farmers Trust Co. now owns 225,881 shares of the biopharmaceutical company’s stock valued at $6,503,000 after buying an additional 4,410 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. BMO Capital Markets reaffirmed an “outperform” rating and issued a $36.00 price target (up previously from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Morgan Stanley boosted their price target on Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research note on Thursday, May 2nd. Argus lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research note on Wednesday. Nine research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, Pfizer currently has a consensus rating of “Hold” and a consensus target price of $35.54.

Pfizer Trading Up 2.3 %

Shares of PFE stock traded up $0.63 on Wednesday, reaching $28.35. 26,872,182 shares of the stock were exchanged, compared to its average volume of 40,021,352. The stock has a market cap of $160.65 billion, a PE ratio of -469.59, a P/E/G ratio of 1.10 and a beta of 0.69. Pfizer Inc. has a one year low of $25.20 and a one year high of $37.80. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.05 and a quick ratio of 0.78. The stock has a 50 day moving average price of $28.18 and a 200 day moving average price of $27.71.

Pfizer (NYSE:PFE) last released its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. The company had revenue of $14.88 billion during the quarter, compared to the consensus estimate of $13.87 billion. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The firm’s quarterly revenue was down 19.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.23 earnings per share. Equities research analysts forecast that Pfizer Inc. will post 2.38 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be given a dividend of $0.42 per share. The ex-dividend date of this dividend is Thursday, July 25th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.93%. Pfizer’s payout ratio is currently -2,799.53%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.